R&D

Pipeline

HOME  >  R&D  >  Pipeline

The problem and market of Arthritis

The problem

1 The nonspecific immune suppression by TNF-α inhibitor

2 one-third of patients do not respond adequately to TNF-α inhibitors

3 some patients may respond initially but lose sensitivity over time

4 increased incidence of infections like tuberculosis, bacterial infections, septic arthritis, and opportunistic infections

5 high cost of the biologics

The market

시장현황

The mechanism of biologics for RA
Blocking tumor necrosis factor-alpha (TNF-α)
Blocking pro-inflammatory cytokines like interleukin-1 (IL-1)
depletion of B-cells
inhibition of the costimulatory pathway for T-cell activation

NIBEC solution for Arthritis

  • NIBEC solution for Arthritis
  • Target: intracellular inflammatory protein (epigenetic modulation)
  • NIPEP-CARE by itself has cell penetration function, which enables to control intracellular target protein
  • Enhanced cartilage regenerative activity provides additional therapeutic advantage
  • Alternative to current TNF-α inhibitor
  • Current status: preclinical study

Discovery and MOA of NIPEP-CARE

The peptide has superior HDAC inhibition and at the same time, it increases significant chondrogenic activity, as seen in the strong blue alcian staingn compared to anti-TN-alpha antibody. As a result, arthritic animal has been completely healed by the peptide to reach to the normal cartilage level, which is also contrast to anti-TNF-alpha antibody.